Editas Medicine, Inc. EDIT announced that it ... gene editing medicines targeting the BCL11A gene in the fields of SCD and ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

So far, it is the only CRISPR-based product on the global market. Casgevy works by editing the faulty gene in a patient’s bone marrow stem cell, enabling the production of functional haemoglobin.

CRISPR Therapeutics has accomplished something many pure-play gene-editing companies haven't: regulatory approval for a therapy. The biotech's Casgevy, a treatment for sickle cell disease (SCD ...

Casgevy delivers on CRISPR’s original promise that diseases can be genetically cured. In the late 2010s and early 2020s that promise spawned huge excitement and investment; gene-editing biotechs ...

The newest gene therapy treatment, Casgevy, treats sick cell disease and transfusion-dependent beta thalassemia. Its addition means that CHLA provides the most cell and gene therapy treatments for ...

More than 50 authorized treatment centers (ATCs) activated globally for CASGEVY, and more than 50 ... This press release discusses CRISPR/Cas9 gene editing investigational therapies and is not ...

making CRISPR-Cas9 a cut-and-paste tool for gene editing. Vertex Pharmaceutical presented impressive long-term data for its Casgevy treatment. 39 out of 42 patients with SCD were free from VODs ...

The company will need to continue innovating and demonstrating superior efficacy and safety profiles for its therapies to maintain its leadership position in the gene editing field. While Casgevy ...